Passage Bio to Undergo Strategic Review and 75% Restructuring After FDA Rejects PBFT02 Clinical Trial
Passage Bio's clinical development of PBFT02, a gene therapy candidate for frontotemporal dementia (FTD), has been halted after the FDA rejected its proposed single-arm design for the Phase 1/2 trial. The FDA's Biologics Blood Products Advisory Committee (BBAC) requested a randomized, controlled trial (RCT) instead. This decision has led Passage Bio to initiate a strategic review, including potential sale, merger, or partnership, due to the delayed timeline and increased clinical costs.
The FDA's requirement for an RCT raises ethical and technical challenges for gene therapies administered via direct brain surgery. PBFT02 requires a high-risk surgical procedure involving direct injection into the patient's cisterna magna, making a sham surgery in the control group ethically problematic. This stringent requirement for a randomized controlled trial poses significant logistical and ethical hurdles for companies developing gene therapies for rare diseases, potentially leading to the abandonment of promising drug candidates.
To reduce its cash burn rate, Passage Bio has announced a restructuring plan that will reduce its workforce by 75%. As of the end of 2025, the company had 24 full-time employees, and this restructuring will reduce that number to 6, resulting in an estimated $3.3 million in one-time costs. While the company had already reduced its workforce by 55% in January 2025 and secured a cash runway through the first quarter of 2027, this additional reduction reflects the company's decision that independent development of PBFT02 is no longer feasible.
The market for frontotemporal dementia caused by granulinin (GRN) gene mutations is a promising market for degenerative brain diseases, estimated to be worth over $2 billion. Currently, there are no approved curative treatments for this condition. Alector's latozinemab and Aviado Bio's AVB-101 are competing in this market, and Passage Bio's withdrawal is expected to benefit these competitors. This situation highlights the significant impact that stringent regulatory requirements for demonstrating efficacy can have on the ecosystem of small, underfunded biotech companies.
With Passage Bio's PBFT02 gene therapy for frontotemporal dementia (FTD-GRN) facing potential discontinuation due to the FDA's rejection of its single-arm clinical trial design, the short-term competitive landscape of the global FTD-GRN treatment market is expected to shift rapidly towards competitors such as Alector and Aviado Bio. From an investor's perspective, the key factors for the company's short-term valuation recovery will be the value of the cash runway secured through the 75% restructuring and the $3.3 million in costs, as well as the likelihood of a successful M&A transaction. For researchers and industry professionals, the FDA's stringent requirement for randomized controlled trials (RCTs) for surgically administered gene therapies will likely pose a long-term ethical challenge for the development of rare disease treatments. Ultimately, the forced restructuring of small biotechs in the FTD treatment market, which is projected to reach $688.2 million in seven major countries by 2035, could accelerate the contraction of the venture capital environment.